Revue des Maladies Respiratoires Actualites最新文献_第3页

Néoplasies neuroendocrines pulmonaires hors cancers du poumon à petites cellules : tumeurs carcinoïdes et carcinomes neuroendocrines à grandes cellules 非小细胞肺癌的肺神经内分泌肿瘤：类癌和大细胞神经内分泌癌

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 DOI: 10.1016/S1877-1203(25)00083-7

L. Odier , M. Darrason , M. Duruisseaux , T. Walter , L. Gérinière , A. Durand , D. Arpin

{"title":"Néoplasies neuroendocrines pulmonaires hors cancers du poumon à petites cellules : tumeurs carcinoïdes et carcinomes neuroendocrines à grandes cellules","authors":"L. Odier , M. Darrason , M. Duruisseaux , T. Walter , L. Gérinière , A. Durand , D. Arpin","doi":"10.1016/S1877-1203(25)00083-7","DOIUrl":"10.1016/S1877-1203(25)00083-7","url":null,"abstract":"<div><div>Primary pulmonary neuroendocrine neoplasms comprise several distinct entities, corresponding to four main histological subtypes: well-differentiated neuroendocrine tumors, including typical low-grade carcinoids and atypical intermediate grade carcinoids; and small-cell and large-cell neuroendocrine carcinomas of high grade.</div><div>There are specific recommendations for the pre-treatment assessment of carcinoid tumors. Clinical suspicion of a secretory syndrome must be confirmed by appropriate biological tests. In the case of metastatic carcinoid tumors, management begins with controlling any carcinoid secretory syndrome using somatostatin analogues. Oncological treatment is based on an assessment of tumor progression, with the possibility of simple monitoring, local treatment of metastases or even the primary tumor, treatment with somatostatin analogues, everolimus, cabozantinib, or, in cases of tumor aggressiveness, chemotherapy, preferably with the combination of oxaliplatin and gemcitabine. Internal radiotherapy vectorized by 177Lu-Dotatate may be offered on a compassionate use basis. In cases of metastatic large cell neuroendocrine carcinoma, the platinum-etoposide combination is typically used as first-line treatment. However, if RB1 expression is preserved or KRAS/STK11 mutations are present, a platinum-gemcitabine or platinumtaxane combination may be proposed.</div><div>There is no standard second-line treatment, and the therapies typically used in nonsmall cell lung cancer may be proposed, with the exception of pemetrexed.</div></div>","PeriodicalId":53645,"journal":{"name":"Revue des Maladies Respiratoires Actualites","volume":"17 2","pages":"Pages 2S261-2S269"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Les métastases cérébrales et les méningites carcinomateuses des cancers bronchiques 脑转移和支气管癌的致癌脑膜炎

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 DOI: 10.1016/S1877-1203(25)00087-4

C. Decroisette , E. Perrot , P. Tomasini

引用次数: 0

Anticorps conjugués dans le cancer broncho-pulmonaire non à petites cellules : où en sommes-nous ? 非小细胞肺癌的结合抗体：我们在哪里？

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 DOI: 10.1016/S1877-1203(25)00074-6

D. Bruyat , P. Tomasini

引用次数: 0

Le TNM du cancer broncho-pulmonaire : quel bilan radio-anatomique ? 支气管肺癌的NMD：什么放射解剖学检查？

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 DOI: 10.1016/S1877-1203(25)00061-8

G. Ferretti , L. Ruez-Lantuejoul , E. Reymond , A.-C. Toffart , A. Khalil , V. Gounant , S. Boussouar

{"title":"Le TNM du cancer broncho-pulmonaire : quel bilan radio-anatomique ?","authors":"G. Ferretti , L. Ruez-Lantuejoul , E. Reymond , A.-C. Toffart , A. Khalil , V. Gounant , S. Boussouar","doi":"10.1016/S1877-1203(25)00061-8","DOIUrl":"10.1016/S1877-1203(25)00061-8","url":null,"abstract":"<div><div>Non-invasive medical imaging is essential for the management of healthy subjects for screening or patients, whether for the diagnostic assessment of suspected tumor, the extension assessment before making a therapeutic decision in the MDC, or the posttherapeutic evaluation follow-up. Interventional radiology is used to obtain material from image-guided biopsies of the tumor or metastasis, which is essential for the diagnosis of certainty of lung cancer. Currently, the radio-anatomical exploration of patients is essentially based on contrast enhanced computed tomography, sometimes on MRI. CT is completed by functional information of PET FDG scintigraphy. The first objective of this paper is to expose the different anatomical diagnostic methods at our disposal to homogenize practices and optimize patient care. The second objective is to present the modalities of the NSCLC extension assessment, addressing the indications for imaging examinations as well as their limitations. We will consider the place of imaging in the ninth edition of the TNM (TNM-9); developed by the IASLC and adopted by the AJCC and UICC, entered into force on 1 January 2025.</div></div>","PeriodicalId":53645,"journal":{"name":"Revue des Maladies Respiratoires Actualites","volume":"17 2","pages":"Pages 2S60-2S67"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer bronchique à petites cellules de stade étendu : quoi de neuf ? 晚期小细胞肺癌：有什么新消息？

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 DOI: 10.1016/S1877-1203(25)00082-5

D. Moro-Sibilot , S. Ocak , C. Ardin , E. Berton , P. Fournel , A.-C. Toffart

引用次数: 0

La prise en charge du fumeur en pratique quotidienne 在日常生活中照顾吸烟者

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 DOI: 10.1016/S1877-1203(25)00054-0

A.-M. Ruppert , D. Glesener

引用次数: 0

Prise en charge systémique du cancer bronchique non à petites cellules chez les sujets âgés 老年人非小细胞肺癌的系统管理

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 DOI: 10.1016/S1877-1203(25)00090-4

L. Pabst , R. Corre , E. Quoix , C. Mascaux

引用次数: 0

Maladies thromboemboliques et cancer du poumon 血栓栓塞性疾病和肺癌

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 DOI: 10.1016/S1877-1203(25)00092-8

G. Poenou , C. Marie-Sainte , A.-L. Desage , C. Gravelier , S. Accassat , L. Bertoletti

{"title":"Maladies thromboemboliques et cancer du poumon","authors":"G. Poenou , C. Marie-Sainte , A.-L. Desage , C. Gravelier , S. Accassat , L. Bertoletti","doi":"10.1016/S1877-1203(25)00092-8","DOIUrl":"10.1016/S1877-1203(25)00092-8","url":null,"abstract":"<div><div>Lung cancer is among the malignancies most strongly associated with thrombotic risk. This close association is often first revealed either by the diagnosis of pulmonary embolism in a patient with lung cancer or, conversely, by the detection of cancer following a thromboembolic event. The underlying pathophysiology involves multiple risk factors, including cancer-specific mechanisms, treatment-related effects, patient characteristics, and genetic biomarkers. Thrombosis in the context of lung cancer carries significant prognostic implications and must be carefullyconsidered. Pulmonaryembolism, in particular, maybe diagnosed incidentally but should never be underestimated in terms of clinical significance. Specific clinical situations—such as perioperative periods or during certain oncologic treatments—require a rigorous, individualized evaluation of the risk-benefit balance regarding the initiation of thromboprophylaxis. This need for personalized risk assessment comes from the delicate equilibrium between thrombosis and bleeding in patients with lung cancer. In patients who have already experienced a thrombotic event, the use of direct oral anticoagulants is a valid therapeutic option, provided that thrombotic and hemorrhagic risks, contraindications, and potential drug-drug interactions are carefully evaluated.</div></div>","PeriodicalId":53645,"journal":{"name":"Revue des Maladies Respiratoires Actualites","volume":"17 2","pages":"Pages 2S341-2S349"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Algorithme thérapeutique des CBNPC sans anomalie moléculaire actionnable en première ligne de traitement 一线治疗无可操作分子异常的CBNPC治疗算法

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 DOI: 10.1016/S1877-1203(25)00072-2

A.-C. Toffart , J. Mazières , M. Pérol , E. Berton , A. Cortot , D. Moro-Sibilot

{"title":"Algorithme thérapeutique des CBNPC sans anomalie moléculaire actionnable en première ligne de traitement","authors":"A.-C. Toffart , J. Mazières , M. Pérol , E. Berton , A. Cortot , D. Moro-Sibilot","doi":"10.1016/S1877-1203(25)00072-2","DOIUrl":"10.1016/S1877-1203(25)00072-2","url":null,"abstract":"<div><div>The development of immunotherapy in first-line therapy with anti-PD-1 and anti-PD-L1 has changed the first line treatment algorithm of advanced non-small cell lung cancer (NSCLC). The anti-PD-(L)1 atézolizumab, cemiplimaband pembrolizumab clearly improve the overall survival in NSCLC with high PD-L1 expression (> 50% of tumour cells), comparatively to cytotoxic chemotherapy. Combinations of anti-PD(L)-1 to platinum-based chemotherapy are superior to chemotherapy alone, regardless of PD-L1 level of expression. They represent the 1st line gold-standard when PD-L1 is expressed in less than 50% of tumour cells and might reduce the risk of early disease progression in comparison with pembrolizumab when PD-L1 > 50%. The room for anti-CTLA-4 + anti-PD(L)-1 combinations which are not available in France remains to be established. Immunotherapy still benefits only a minority of patients whose identification is imperfect, underscoring the need for new strategies based on new combinations amplifying the anti-tumour immune response as well as understanding the mechanisms of resistance to treatment in order to improve these results.</div></div>","PeriodicalId":53645,"journal":{"name":"Revue des Maladies Respiratoires Actualites","volume":"17 2","pages":"Pages 2S151-2S159"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quand et comment réaliser un staging ganglionnaire ? 什么时候以及如何进行节育器阶段？

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 DOI: 10.1016/S1877-1203(25)00063-1

D. Basille

{"title":"Quand et comment réaliser un staging ganglionnaire ?","authors":"D. Basille","doi":"10.1016/S1877-1203(25)00063-1","DOIUrl":"10.1016/S1877-1203(25)00063-1","url":null,"abstract":"<div><div>Mediastinal lymph node staging is a critical step in the therapeutic management of non-small cell lung cancer (NSCLC). Advances in functional imaging, particularly PET-CT, have significantly improved non-invasive diagnosis. However, its limited specificity makes histological confirmation essential.</div><div>Minimally invasive endoscopic techniques, endobronchial ultrasound (EBUS) ± endoscopic ultrasound (EUS), have emerged as first-line modalities due to their low morbidity and high diagnostic accuracy, especially in patients eligible for curative treatment. These techniques are particularly recommended in cases of radiologically suspicious lymphadenopathy (cN1-N3), central tumors, or large tumors (>3 cm). In the event of negative findings but persistent clinical suspicion, surgical staging via mediastinoscopy remains indicated. Nevertheless, the systematic use of this surgical approach following complete endoscopic staging is increasingly debated in light of recent evidence.</div><div>In patients with early-stage NSCLC classified as N0 on PET, invasive staging prior to stereotactic body radiotherapy is not routinely recommended but should be considered on a case-by-case basis, depending on clinical and anatomical risk factors.</div><div>Finally, in locally advanced disease treated with neoadjuvant therapy, mediastinal restaging remains a pivotal step in guiding further management. However, it is technically more challenging due to treatment-induced changes such as fibrosis and adhesions, and requires an individualized approach combining both endoscopic and surgical techniques. 1877-1203/© 2025 SPLF. Published by Elsevier Masson SAS. All rights reserved.</div></div>","PeriodicalId":53645,"journal":{"name":"Revue des Maladies Respiratoires Actualites","volume":"17 2","pages":"Pages 2S75-2S83"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0